Wire · opportunities
FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 August 2026 · Fusion42 review
The FDA approved Eli Lilly's Mounjaro (tirzepatide) to reduce major cardiovascular events in adults with type 2 diabetes at high risk. This follows clinical trial results showing non-inferiority and 8% lower risk of cardiovascular death, heart attack, or stroke compared to Trulicity (dulaglutide).
This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You face a new standard in cardiovascular risk reduction for type 2 diabetes treatment as Mounjaro sets a higher bar than existing therapies. This regulatory approval opens fresh market access opportunities for competing therapies and reshapes diabetic cardiovascular care.
◆ Coverage
2 sources · 28 Aug 2026
◆ Related on Wire
◆ Topics